fianlimab
Sponsor Regeneron Pharmaceuticals, INC. · listed as REGN
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-07-27
As disclosedJul 27, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT05608291
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorRegeneron Pharmaceuticals
Listed asREGN
Condition(s)Melanoma
All tracked catalysts for fianlimab
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-07-27 | READOUT | medium | NCT05608291 |
| 2027-03-22 | READOUT | medium | NCT06246916 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More REGN catalysts